Amneal Pharmaceuticals, Inc.
AMRX
Rang in aandelen
#2928
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Aandeelprijs
$19.83
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$6.33B
Verandering (1 dag)
2.43%
Verandering (1 jaar)
92.71%
Land
US
Handel Amneal Pharmaceuticals, Inc. (AMRX)
Categorie
Healthcare
Omzet van Amneal Pharmaceuticals, Inc. (AMRX)
Omzet in Jun 2026 TTM: $3.12B
Volgens de laatste financiële rapporten van Amneal Pharmaceuticals, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $3.12B. In 2023 behaalde het bedrijf een omzet van $2.39B een stijging ten opzichte van de omzet in het jaar 2022, die $2.21B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Amneal Pharmaceuticals, Inc. van 2014 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $3.12B | 11.58% |
| 2024 | $2.79B | 16.73% |
| 2023 | $2.39B | 8.20% |
| 2022 | $2.21B | 5.67% |
| 2021 | $2.09B | 5.08% |
| 2020 | $1.99B | 22.51% |
| 2019 | $1.63B | -2.20% |
| 2018 | $1.66B | 60.88% |
| 2017 | $1.03B | 1.52% |
| 2016 | $1.02B | 17.54% |
| 2015 | $866.28M | 10.27% |
| 2014 | $785.62M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 112.08% |
IN
|
